T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2276
Scansource
SCSC
$1.06B
| $630K | ﹤0.01% |
16,106
+1,373
| +9% | +$56.7K |
|
2277
Trevi Therapeutics
TRVI
$2.53B
| $630K | ﹤0.01% |
50,273
+3,414
| +7% | +$39.5K |
|
2278
Perella Weinberg Partners
PWP
$1.28B
| $628K | ﹤0.01% |
36,300
+3,049
| +9% | +$56.9K |
|
2279
Helix Energy Solutions
HLX
$1.49B
| $623K | ﹤0.01% |
99,340
+9,702
| +11% | +$64.5K |
|
2280
Matrix Service
MTRX
$330M
| $623K | ﹤0.01% |
53,212
+5,795
| +12% | +$72.8K |
|
|
GOOD
2281
Gladstone Commercial Corp
GOOD
$630M
| $622K | ﹤0.01% |
58,213
+19,841
| +52% | +$220K |
|
2282
Sprinklr
CXM
$1.58B
| $619K | ﹤0.01% |
79,459
-48,263
| -38% | -$367K |
|
|
RC
2283
Ready Capital
RC
$289M
| $617K | ﹤0.01% |
282,870
+113,128
| +67% | +$317K |
|
2284
Atlanticus Holdings
ATLC
$1.48B
| $616K | ﹤0.01% |
9,194
+478
| +5% | +$28.1K |
|
2285
Nu Skin
NUS
$236M
| $616K | ﹤0.01% |
63,981
-2,835
| -4% | -$29.3K |
|
2286
Phathom Pharmaceuticals
PHAT
$742M
| $616K | ﹤0.01% |
37,071
+5,152
| +16% | +$73.6K |
|
|
FLOC
2287
Flowco Holdings
FLOC
$1.04B
| $616K | ﹤0.01% |
32,856
+2,019
| +7% | +$33.7K |
|
|
GPGI
2288
GPGI Inc
GPGI
$3.85B
| $613K | ﹤0.01% |
31,793
+7,779
| +32% | +$155K |
|
|
ORC
2289
Orchid Island Capital
ORC
$1.32B
| $612K | ﹤0.01% |
84,975
+12,614
| +17% | +$91.8K |
|
2290
ProPetro Holding
PUMP
$1.42B
| $610K | ﹤0.01% |
64,086
+20,237
| +46% | +$176K |
|
|
BORR
2291
Borr Drilling
BORR
$1.25B
| $609K | ﹤0.01% |
150,914
+12,004
| +9% | +$39.8K |
|
2292
Bristow Group
VTOL
$1.36B
| $609K | ﹤0.01% |
16,616
+1,078
| +7% | +$40.6K |
|
2293
Evolv Technologies
EVLV
$1.04B
| $607K | ﹤0.01% |
84,692
+22,710
| +37% | +$161K |
|
2294
MiMedx Group
MDXG
$624M
| $607K | ﹤0.01% |
89,539
+4,700
| +6% | +$32.9K |
|
2295
Bitdeer Technologies
BTDR
$2.38B
| $606K | ﹤0.01% |
53,977
+5,106
| +10% | +$82.3K |
|
2296
LendingTree
TREE
$444M
| $606K | ﹤0.01% |
11,398
+612
| +6% | +$34.3K |
|
2297
Keros Therapeutics
KROS
$222M
| $605K | ﹤0.01% |
29,699
-20,282
| -41% | -$356K |
|
2298
First Community Bankshares
FCBC
$927M
| $599K | ﹤0.01% |
17,749
-264
| -1% | -$8.82K |
|
|
BDN
2299
Brandywine Realty Trust
BDN
$541M
| $598K | ﹤0.01% |
204,550
-2,995
| -1% | -$10.2K |
|
2300
Primis Financial Corp
FRST
$411M
| $595K | ﹤0.01% |
42,768
+1,667
| +4% | +$18.9K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.